Tenax Therapeutics Shares Double Premarket After FDA Clears IND for TNX-103
By Chris Wack
Tenax Therapeutics shares doubled to 35 cents in premarket trading after the company said that the U.S. Food and Drug Administration has reviewed and cleared its Investigational New Drug Application for TNX-103 for the treatment of pulmonary hypertension with heart failure.
The FDA's clearance allows the specialty pharmaceutical company to proceed with the first of two Phase 3 studies.
The study is expected to launch in the fourth quarter of 2023.
Tenax said that the clearance means it won't be required to conduct a long-term, cardiovascular outcomes trial, which should significantly reduce costs and time to registration for TNX-103.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 13, 2023 09:09 ET (14:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths